



WHAT IS CLAIMED IS:

1. A compound of formula (I),




- 5 or a pharmaceutically suitable salt or prodrug thereof, wherein

A is a member selected from the group consisting of



B and C are each independently a member selected from the group consisting of aryl, and heterocycle;

- 10 R<sub>1</sub> is a member a member selected from the group consisting of alkyl, alkoxy, alkylSO<sub>2</sub>, trifluoroalkylSO<sub>2</sub>, trifluoroalkylNH-, alkylSO<sub>2</sub>NH-, carboxy, cyano, HONHcarbonyl, R<sub>a</sub>ONHcarbonyl, nitro, R<sub>a</sub>OC(O)-, HO<sub>3</sub>S-, H<sub>2</sub>NO<sub>2</sub>S-, R<sub>a</sub>NHO<sub>2</sub>S-, (HO)<sub>2</sub>(O)P-, (HO)<sub>2</sub>(O)PCH<sub>2</sub>-, (HO)<sub>2</sub>(O)PCHF-, (HO)<sub>2</sub>(O)PCF<sub>2</sub>- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



$R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl,  $R_a R_b N$ ,  $R_a R_b N$ alkyl,  $R_a R_b N$ carbonyl,  $R_a R_b N$ carbonylalkyl,  $R_a R_b N N$ sulfonyl,  $R_a R_b N N$ sulfonylalkyl, wherein  $R_a$  and  $R_b$  are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy carbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;


L is  $-G-X_1-J-X_2-K-$  or a bond;

$G$ ,  $J$  and  $K$  are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and  $R_d R_e N-$ , wherein  $R_d$  and  $R_e$  are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy carbonyl, alkylcarbonyl and arylalkyl;

$X_1$  and  $X_2$  are each independently a member selected from the group consisting of a bond,  $-O-$ ,  $-N(R_c)-$ ,  $-N(R_c)C(O)-$ ,  $-C(O)N(R_c)-$ ,  $-N(R_c)S(O)_2-$ ,  $-S(O)_2N(R_c)-$ , and  $-C(O)-$ , wherein  $R_c$  is a member selected from the group consisting of hydrogen, alkyl and arylalkyl; and

provided that if J is absent, then at least one of  $X_1$  and  $X_2$  must be absent.


2. A compound of formula (II),



(II),

or a pharmaceutically suitable salt or prodrug thereof, wherein

R<sub>1</sub> is a member selected from the group consisting of alkyl, alkoxy, alkylSO<sub>2</sub>, trifluoroalkylSO<sub>2</sub>, trifluoroalkylNH-, alkylSO<sub>2</sub>NH-, carboxy, cyano, HONHcarbonyl, R<sub>a</sub>ONHcarbonyl, nitro, R<sub>a</sub>OC(O)-, HO<sub>3</sub>S-, H<sub>2</sub>NO<sub>2</sub>S-, R<sub>a</sub>NHO<sub>2</sub>S-, (HO)<sub>2</sub>(O)P-, (HO)<sub>2</sub>(O)PCH<sub>2</sub>-, (HO)<sub>2</sub>(O)PCHF-, (HO)<sub>2</sub>(O)PCF<sub>2</sub>- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl,

heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl,  $R_aR_bN$ ,  $R_aR_bNalkyl$ ,  $R_aR_bNcarbonyl$ ,  $R_aR_bNcarbonylalkyl$ ,  $R_aR_bNNSulfonyl$ ,  $R_aR_bNNSulfonylalkyl$ , wherein  $R_a$  and  $R_b$  are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;

L is  $-G-X_1-J-X_2-K-$  or a bond;

G, J and K are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and  $R_dR_eN-$ , wherein  $R_d$  and  $R_e$  are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl and arylalkyl;

$X_1$  and  $X_2$  are each independently a member selected from the group consisting of a bond,  $-O-$ ,  $-N(R_c)-$ ,  $-N(R_c)C(O)-$ ,  $-C(O)N(R_c)-$ ,  $-N(R_c)S(O)_2-$ ,  $-S(O)_2N(R_c)-$ , and  $-C(O)-$ , wherein  $R_c$  is a member selected from the group consisting of hydrogen, alkyl and arylalkyl; and

provided that if J is absent, then at least one of  $X_1$  and  $X_2$  must be absent.

3. The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl.

4. The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl;

and

$X_1$ , J and K are a bond.

5. The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl;

and

$X_1$ , J and K are a bond; and

$R_1$  is  $CO_2H$ .

6. The compound according to claim 5, a member selected from the group consisting of 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-

carboxylic acid;

5-(3-((2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)propyl)phenyl)isoxazole-3-carboxylic acid;

5-(2-fluoro-5-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1S,2S)-2-((3-hydroxy-2-(methoxycarbonyl)phenoxy)methyl)cyclopropyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)-4-methoxyphenyl)isoxazole-3-carboxylic acid;

5-(4-fluoro-3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)pentyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-propionylphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-4-hydroxy-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)but-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(1-(2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)-1H-indol-6-yl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(2-(acetylamino)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(2-((benzylamino)carbonyl)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)-4-nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

4-amino-5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-((3',5'-dihydroxy-4-(methoxycarbonyl)-1,1'-biphenyl-3-yl)oxy)prop-1-

enyl)phenyl)isoxazole-3-carboxylic acid; and

5-(3-((1*E*)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)-4-(hydroxymethyl)isoxazole-3-carboxylic acid.

7. The compound according to claim 2, wherein

X<sub>1</sub> is a member selected from the group consisting of -NH- and -NHC(O)-.

8. The compound according to claim 2, wherein

X<sub>1</sub> is a member selected from the group consisting of -NH- and -NHC(O)-; and

G and K are a bond.

9. The compound according to claim 2, wherein

X<sub>1</sub> is a member selected from the group consisting of -NH- and -NHC(O)-;

G and K are a bond; and

R<sub>1</sub> is CO<sub>2</sub>H.

10. The compound according to claim 9, a member selected from the group consisting of 5-(3-(((1-acetylpiperidin-4-yl)carbonyl)amino)phenyl)isoxazole-3-carboxylic acid;

5-(3-((2-(3-hydroxy-2-

((methylamino)carbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid; and

5-(3-((1*E*)-3-(3-hydroxy-2-((methylamino)carbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid.

11. The compound according to claim 2 wherein

L is a bond.

12. The compound according to claim 2 wherein

L is a bond; and

R<sub>1</sub> is CO<sub>2</sub>H.

13. The compound according to claim 12 that is

5-{3'-(3-(carboxy)isoxazol-5-yl)-1,1'-biphenyl-3-yl}isoxazole-3-carboxylic acid.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

15. A method of selectively inhibiting protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

5 16. A method of treating disorders caused by overexpressed or altered protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

10 17. A method of treating type I and type II diabetes, impaired glucose tolerance and insulin resistance, comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

15 18. A method of treating obesity comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

20 19. A method of treating autoimmune disorders, acute and chronic inflammatory disorders, osteoporosis, cancer, malignant disorders comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.